Bria-IMT is a Gene-Modified Cell Therapy owned by BriaCell Therapeutics, and is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 is planned.

Bria-IMT (SVBR-1-GM) is employed in the synthesis of naturally occurring cytokine GM-CSF from genetically engineered breast cancer cell line. GM-CSF stimulates potent, long-lasting, and tumor-specific immunity and also stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. GM-CSF generates type 1 dendritic cells (DC1), which can skew T-cells toward a Th-1 phenotype generating anti-tumor effects. Bria-IMT also activate CD4+ “Helper” T cells, a key component of the immune system, which may produce a vigorous attack on tumor cells resulting in clinical tumor regressions (i.e., reduction in the tumor size).

The revenue for Bria-IMT is expected to reach a total of $255m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bria-IMT NPV Report.

Bria-IMT is originated and owned by BriaCell Therapeutics.

Bria-IMT Overview

Bria-IMT (BriaVax) is under development for the treatment of advanced metastatic breast cancer, triple-negative breast cancer, HER2+ breast cancer and HER2- breast cancer. The vaccine candidate  is administered intradermally. The vaccine candidate is a HER2/neu-positive allogeneic (non-self) breast cancer cell line (SV-BR-1) transfected with the GM-CSF gene to produce the naturally occurring cytokine GM-CSF.

BriaCell Therapeutics Overview

BriaCell Therapeutics is a healthcare services provider company. The company develops novel immunotherapies cutting-edge technology to fight cancer. Its services include BRIA-IMT technology, BRIA-OTS technology, PKCd technology, patents technology, mechanism of action technology, and clinical trials and technology services. BriaCell Therapeutics also develops diagnostic testing products and technology, business technology development, proprietary technology, and potential combination treatment options to treat various cancer indications. The company Bria-IMT a targeted immunotherapy being developed for the treatment of breast cancer and genetically engineered human breast cancer cell line with features of immune cells and clinically applied as a targeted immunotherapy. It has operations in the US and Canada. BriaCell Therapeutics is headquartered in West Vancouver, British Columbia, Canada.

The operating loss of the company was US$15.3 million in FY2022, compared to an operating loss of US$7.1 million in FY2021. The net loss of the company was US$26.8 million in FY2022, compared to a net loss of US$13.8 million in FY2021.

Quick View – Bria-IMT

Report Segments
  • Innovator
Drug Name
  • Bria-IMT
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.